Chemotherapy combined with selective resection in small cell lung cancer--analysis of 239 patients
Cao, Y.F.; Xu, C.W.; Liao, M.L.; Fang, M.S.; Yang, X.F.; Wu, S.Z.; Chen, Y.R.; Wu, S.F.; Huang, O.L.; Wu, S.C.
Zhonghua Zhong Liu Za Zhi 8(5): 381-385
1986
ISSN/ISBN: 0253-3766 PMID: 2436869 Document Number: 282395
From 1957 to 1976, 143 patients with small cell lung cancer (SCLC) were treated with surgical resection followed by chemotherapy. The 5 year survival rates were 38.7%, 8.7% and 3.5% in stages I, II and III. The prognostic factors were clinical stage and chemotherapy. 4 stage I and 1 stage II patients without chemotherapy have survived for more than 5 years. It seems to suggest that SCLC in stage I be indicated for surgery. 4 stage III have survived for more than 5 years, all of whom had received postoperative chemotherapy for more than 4 courses. From 1980 to 1982, 96 patients with SCLC were treated, 37 of whom by chemotherapy combined with surgery. 11/37 patients were alive for more than 2 years, 7 for more than 3 years and 4 for more than 4 years. In the preoperative chemotherapy followed by selective resection plus postoperative chemotherapy group (13 patients), the mean survival time was 22.7 months, but in the postoperative chemotherapy group (24 patients), it was 11.0 months. It indicates that full-dose chemotherapy before and after operation may be superior to the postoperative chemotherapy alone.